REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
305.24
-2.18 (-0.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close307.42
Open306.81
Bid302.00 x 900
Ask308.88 x 800
Day's Range304.00 - 315.20
52 Week Range295.27 - 442.00
Volume624,172
Avg. Volume814,360
Market Cap33.322B
Beta (3Y Monthly)1.05
PE Ratio (TTM)14.46
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com5 hours ago

    2 Well-Known Stocks You Should Consider Shorting This Week

    Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.

  • Here’s What Hedge Funds Think About Regeneron Pharmaceuticals Inc (REGN)
    Insider Monkey3 days ago

    Here’s What Hedge Funds Think About Regeneron Pharmaceuticals Inc (REGN)

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling
    Simply Wall St.5 days ago

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Barrons.com6 days ago

    The Regeneron Stock Selloff Is Driven by Fear, Not Substance, Analyst Says

    Regeneron (ticker: REGN) markets drugs for a range of conditions, including rheumatoid arthritis and various forms of cancer, and shares have struggled since last fall. Regeneron stock is among the worst-performing of the large biotech companies. In May, the company announced earnings that fell short of analyst expectations, as Barron’s reported.

  • Here's Why Regeneron Pharmaceuticals Tumbled 12% in May
    Motley Fool7 days ago

    Here's Why Regeneron Pharmaceuticals Tumbled 12% in May

    Sales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $14.50 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MoneyShow7 days ago

    Regeneron- A Rich Research Pipeline

    Regeneron Pharmaceuticals (REGN) recently had a rough earnings release; the biotech firm reported first-quarter revenue of $1.71 billion, a 13% year-over-year jump but about $50 million lower than analysts' expectation, asserts Scott Chan, editor of The Complete Investor.

  • Benzinga9 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

    Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...

  • Alnylam Completes Rolling NDA Submission to FDA for Givosiran
    Zacks11 days ago

    Alnylam Completes Rolling NDA Submission to FDA for Givosiran

    Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

  • Why Is Regeneron (REGN) Down 8.8% Since Last Earnings Report?
    Zacks11 days ago

    Why Is Regeneron (REGN) Down 8.8% Since Last Earnings Report?

    Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
    Zacks12 days ago

    Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

    GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

  • Reuters13 days ago

    Sanofi loses German patent case against Amgen over cholesterol drug

    Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent. In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special licence that would have protected its Praluent business. Officials at Sanofi did not have an immediate comment.

  • Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition
    American City Business Journals17 days ago

    Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

    Cambridge-based Epizyme is now awaiting FDA for approval for its epigenetics first product, tazemetostat, with plans to quickly expand its applications.

  • Save the Date: 11 Biotech Stocks to Put on Your Radar
    Kiplinger18 days ago

    Save the Date: 11 Biotech Stocks to Put on Your Radar

    This is the time of year when stocks are sleepy at best, and at worst, prone to pullbacks.That's not necessarily true of all equities, however. Some groups are very active and perform quite well in the summer months. Pharmaceutical stocks - and especially biotech stocks - fare pretty well this time of year.Part of that cyclical strength stems from how the Food and Drug Administration schedules key decision-making dates for new drugs. Another part of it may be the result of recurring industry conferences, where many drug-development updates are unveiled.Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months. Because biotechnology companies' shares tend to hinge heavily on product updates, this seasonal tide of news could move their respective stocks well before (and even long after) the day the news is posted. Just be cautious; smaller biotechnology stocks with one or just a couple of trial products can move drastically on new data - for better or for worse. SEE ALSO: 20 Great Stocks That You Haven't Heard Of

  • Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
    Zacks19 days ago

    Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate

    Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.

  • Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service
    Zacks25 days ago

    Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service

    Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service

  • 5 Oversold Stocks That Can Rebound Amid the Trade War
    Investopedia27 days ago

    5 Oversold Stocks That Can Rebound Amid the Trade War

    Despite escalating trade tensions, a number of stocks are looking relatively cheap compared to the past as well as future growth prospects.

  • Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
    Zacks28 days ago

    Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

    Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.

  • Barrons.com28 days ago

    5 Cheap Stocks to Ride Out the Trade War

    Investors shopping for stocks are better off simply favoring cheap ones with decent long-term growth prospects, rather than reacting to each new development on tariffs and other fleeting factors.

  • Thomson Reuters StreetEvents28 days ago

    Edited Transcript of REGN earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Regeneron Pharmaceuticals Inc Earnings Call

  • Moving Average Crossover Alert: Regeneron Pharmaceuticals
    Zackslast month

    Moving Average Crossover Alert: Regeneron Pharmaceuticals

    Regeneron Pharmaceuticals, Inc. (REGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Barrons.comlast month

    Regeneron Cancer Drug Gives Anxious Investors Hope

    Anxious investors in the biotech firm (REGN)(ticker: REGN), shares of which fell early this month after its first-quarter earnings missed Wall Street expectations, woke up to happy news this morning. Regeneron has tanked over the past three months, down 27% since mid-February. Shares haven’t budged on Regeneron’s Libtayo news.

  • MarketWatchlast month

    Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer

    Oppenheimer initiated coverage of Outlook Therapeutics Inc's stock on Thursday at a price target of $12, while giving it an outperform rating. It's a big show of confidence for the tiny biotech, whose shares shot up 26% on Thursday morning and are now trading at around $1. Outlook is investigating a formulation of bevacizumab it calls ONS-5010, meant to treat wet age-related macular degeneration. The main wet AMD drugs right now are Genentech's Lucentis, Regeneron Pharmaceuticals Inc's Eylea and Avastin, also by Genentech. Avastin, an oncology drug used off label to treat wet AMD, is popular among providers and payers because it's cheaper than Lucentis and Eylea. However, risk of contamination has been a concern for the FDA, and Oppenheimer thinks ONS-5010 could one day end up taking over Avastin's large share of the AMD space. Shares of the company have fallen 71% in the year to date, while the S&P 500 has gained 14.4%.

  • Pfizer's Eczema Candidate Meets All Goals in Phase III Study
    Zackslast month

    Pfizer's Eczema Candidate Meets All Goals in Phase III Study

    Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

  • Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
    Zackslast month

    Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates

    Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.